Majid Ghoddusi, D.V.M, Ph.D.

Majid joined Janux in June 2022 as the head of clinical biomarkers responsible to devise and implement biomarkers strategies, source best technologies and platforms, and execute comprehensive laboratory testing plans and data analysis in support of Janux clinical studies. Majid has over 15 years of experience in some of the most challenging areas of oncology therapeutics with a primary focus on identifying predictive biomarkers as a crucial part of oncology clinical development. Trained as a translational pathologist he has held impactful positions with increasing responsibilities at large pharmaceuticals and small to medium biotech companies including Novartis, Celgene, Juno Therapeutics, Five Prime, and Poseida Therapeutics.

Majid earned a Doctor of Veterinary Medicine degree from Iran, a Postgraduate Diploma and a PhD in pathology and pathobiology from the University of Queensland in Australia. He has been part of the teams that has helped FDA approval of anti-CD19 CAR-T Breyanzi in DLBCL and the BRAF-inhibitor Encorafenib in melanoma.